LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Sarepta Therapeutics Inc

Cerrado

SectorSalud

17.09 -0.81

Resumen

Variación precio

24h

Actual

Mínimo

16.97

Máximo

17.65

Métricas clave

By Trading Economics

Ingresos

-607M

-448M

Ventas

86M

745M

P/B

Media del Sector

27.205

50.291

BPA

-3.42

Margen de beneficio

-60.08

Empleados

1,372

EBITDA

-560M

-369M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+147.88% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-8.5B

1.9B

Apertura anterior

17.9

Cierre anterior

17.09

Noticias sobre sentimiento de mercado

By Acuity

100%

0%

364 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Sarepta Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

31 mar 2025, 14:19 UTC

Principales Movimientos del Mercado

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

17 jun 2025, 09:10 UTC

Acciones populares

Stocks to Watch Tuesday: SunRun, Enphase Energy, Mitsubishi, Roku -- WSJ

17 jun 2025, 08:59 UTC

Acciones populares

Stocks to Watch Tuesday: Sunrun, Enphase Energy, Mitsubishi, Roku -- WSJ

16 jun 2025, 08:55 UTC

Acciones populares

Stocks to Watch: Victoria's Secret, Renault, U.S. Steel, Sarepta -- WSJ

Comparación entre iguales

Cambio de precio

Sarepta Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

147.88% repunte

Estimación a 12 meses

Media 42.71 USD  147.88%

Máximo 98 USD

Mínimo 10 USD

De acuerdo con 26 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sarepta Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

26 ratings

12

Comprar

13

Mantener

1

Vender

Puntuación técnica

By Trading Central

N/A / 62.47Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

364 / 380 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.